Alamar Biosciences has partnered with GSK to use its NULISA platform for a large-scale proteomic study analyzing over 60,000 serum samples. The study aims to identify protein signatures linked to disease progression, biological subtypes, and treatment responses across multiple conditions including respiratory, liver, kidney, neurological, and autoimmune diseases. This collaboration seeks to enhance precision medicine by improving disease classification and enabling earlier detection and personalized treatment. The insights gained could also inform drug development and clinical trial design.
GSK shares trade at USD 48.60 on Pluang as of Nov 04, 2026 04:11 WIB, showing a slight 0.29% decline in the past day. The stock holds a market cap of $97.85 billion and a dividend yield of 3.7%, with a typical hold time of 95 days among Pluang investors. This trading activity provides context to GSK's ongoing collaboration with Alamar Biosciences on a large-scale proteomic study aimed at advancing precision medicine.
